Unidade de Investigación en Cardioloxía Celular e Molecular
C.C.M.
![Foto de Unidade de Investigación en Cardioloxía Celular e Molecular](/img/grupo.png)
![Foto de Hospital Universitario Virgen de la Victoria](/img/noimage_org.png)
Hospital Universitario Virgen de la Victoria
Málaga, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (21)
2023
-
Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort
International Journal of Infectious Diseases, Vol. 137, pp. 134-143
-
Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study
European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360
-
Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
Patient Preference and Adherence, Vol. 17, pp. 839-849
-
Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020
Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 519-530
2022
-
Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria
Open Forum Infectious Diseases, Vol. 9, Núm. 9
2021
-
Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice
REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48
-
Mural Endocarditis: The GAMES Registry Series and Review of the Literature
Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764
-
Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival
Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21
2020
-
A Contemporary Picture of Enterococcal Endocarditis
Journal of the American College of Cardiology, Vol. 75, Núm. 5, pp. 482-494
-
Reducing residual thrombotic risk in patients with peripheral artery disease: Impact of the COMPASS trial
Drugs in Context, Vol. 9
-
Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition
Expert Review of Clinical Pharmacology, Vol. 13, Núm. 7, pp. 695-706
2019
-
Nutritional risk index predicts survival in patients undergoing transcatheter aortic valve replacement
International Journal of Cardiology, Vol. 276, pp. 66-71
-
Role of age and comorbidities in mortality of patients with infective endocarditis
European Journal of Internal Medicine, Vol. 64, pp. 63-71
2018
-
Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis
Journal of Infection and Chemotherapy, Vol. 24, Núm. 7, pp. 555-562
-
Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial
European Heart Journal, Vol. 39, Núm. 15, pp. 1255-1264
2017
-
Infective endocarditis in patients with cancer: A consequence of invasive procedures or a harbinger of neoplasm? A prospective, multicenter cohort
Medicine (United States), Vol. 96, Núm. 38
-
Prognostic value of body mass index in transcatheter aortic valve implantation: A “J”-shaped curve
International Journal of Cardiology, Vol. 232, pp. 342-347
2015
-
Current epidemiology and outcome of infective endocarditis: A multicenter, prospective, cohort study
Medicine (United States), Vol. 94, Núm. 43
-
Left-sided infective endocarditis in patients with liver cirrhosis
Journal of Infection, Vol. 71, Núm. 6, pp. 627-641
2013
-
In-hospital and mid-term predictors of mortality after transcatheter aortic valve implantation: Data from the Tavi national registry 2010-2011
Revista Espanola de Cardiologia, Vol. 66, Núm. 12, pp. 949-958